Protalex, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1999-01-01
- Employees
- 2
- Market Cap
- -
- Website
- http://www.protalex.com
PRTX-100-203 Open-Label, Dose Escalation Study in Adult Patients With ITP
- First Posted Date
- 2015-10-02
- Last Posted Date
- 2019-03-25
- Lead Sponsor
- Protalex, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT02566603
- Locations
- 🇫🇷
CH Lyon Sud, Pierre-Bénite, Lyon, France
🇫🇷Côte de Nacre Hospital, Caen, France
🇫🇷Mondor Hospital, Créteil, France
PRTX-100-202 Open-Label, Dose Escalation Study in Adult Patients With ITP
- First Posted Date
- 2015-03-27
- Last Posted Date
- 2019-07-05
- Lead Sponsor
- Protalex, Inc.
- Target Recruit Count
- 13
- Registration Number
- NCT02401061
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Gabrail Cancer Center, Canton, Ohio, United States
🇺🇸Cleveland Clinic Foundation, Cleveland, Ohio, United States
6-Month Phase I/II Open Label PRTX-100 in Previous Rheumatoid Arthritis Study Participants and Sera Collection
- First Posted Date
- 2015-01-05
- Last Posted Date
- 2018-10-16
- Lead Sponsor
- Protalex, Inc.
- Target Recruit Count
- 13
- Registration Number
- NCT02330445
- Locations
- 🇺🇸
Protalex Investigational Site, Coeur d'Alene, Idaho, United States
Safety Study of PRTX-100 With Methotrexate or Leflunomide to Treat Active Rheumatoid Arthritis
Phase 1
Completed
- Conditions
- Arthritis, Rheumatoid
- Interventions
- First Posted Date
- 2012-12-17
- Last Posted Date
- 2014-12-23
- Lead Sponsor
- Protalex, Inc.
- Target Recruit Count
- 61
- Registration Number
- NCT01749787
- Locations
- 🇺🇸
Protalex Investigational Site, Allen, Texas, United States
🇺🇸Protalex Investigative Site, Los Angeles, California, United States
Phase I Safety and Tolerability Study of Staphylococcal Protein A in Adult Patients With Chronic ITP
Phase 1
Terminated
- Conditions
- Idiopathic Thrombocytopenic Purpura (ITP)
- Interventions
- First Posted Date
- 2007-12-12
- Last Posted Date
- 2018-07-20
- Lead Sponsor
- Protalex, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT00571467
- Locations
- 🇦🇺
St. George Hospital, Sydney, New South Wales, Australia
🇦🇺Canberra Hospital, Garran, Australian Capital Territory, Australia
🇦🇺Royal Brisbane, Brisbane, Queensland, Australia
Phase 1 Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of PRTX-100 in Healthy Adult Volunteers
Phase 1
Completed
- Conditions
- Healthy Volunteers
- First Posted Date
- 2007-08-17
- Last Posted Date
- 2008-05-06
- Lead Sponsor
- Protalex, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT00517855
- Locations
- 🇺🇸
Buffalo Clinical Research Center, Buffalo, New York, United States
© Copyright 2025. All Rights Reserved by MedPath